PAM
STAB

Panagora Asset Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Panagora Asset Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,427
Closed -$42K – 2423
2017
Q4 		$42K Buy
+10,427
New +$31.7K ﹤0.01% 2081

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Panagora Asset Management's STAB Position: Q1 2018 in Review

Panagora Asset Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2018, closing a stake of 10,427 shares — an estimated $42K sold.

Panagora Asset Management first reported a position in STAB in Q4 2017 and held it in 1 quarter. The position peaked at $42K in Q4 2017. 16 funds tracked by Wall St. Rank hold STAB as of Q1 2018.

  • Panagora Asset Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Panagora Asset Management sold 10,427 Statera Biopharma, Inc. Common Stock shares in Q1 2018, an estimated $42K.
  • Panagora Asset Management first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Panagora Asset Management's Statera Biopharma, Inc. Common Stock position peaked at $42K in Q4 2017.
  • 16 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2018.

Based on Panagora Asset Management's 13F filing for Q1 2018, filed 15 May 2018.